Although the exact role of CAF subtypes in tumor progression is not yet fully understood, several studies have demonstrated that myCAFs can induce the expression of PD-1 and CTLA-4 in Treg through a positive feedback loop, suggesting that myCAFs hold potential as viable targets for cancer immunotherapy [159,160]. This evidence concerns the gene PDCD1 and cancer.